옵션 체인은 다양한 행사가격과 만기일에 대한 Johnson & Johnson의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Johnson & Johnson에 대한 시장 심리를 평가합니다..

Johnson & Johnson (NYSE:JNJ) 주식, 옵션 체인

Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

News

Markets

Tech

AAPL

AMZN

NVDA

엔비디아(NASDAQ:NVDA)는 생물학 연구 분야의 혁신을 목표로 하는 고급 인공지능(AI) 시스템인 에보2(Evo 2)를 출시했다.

엔비디아의 새로운 AI 시스템 &#39;에보2&#39;, 속도와 정밀성으로 유전 연구 변화 목표

Politics

Trading Ideas

MSFT

TSLA

최근 몇 년 동안 주식 매매에서 가장 활발한 활동을 보여준 미국 의원 중 한 명은 조시 고트하이머(민주-뉴저지)이다. 그는 최근 벤징가의 정부 거래 페이지에 보고된 대로 수십 건의 새로운 거래를 공개했다.

조시 고트하이머 의원, 엔비디아와 마이크로소프트를 처분하고 테슬라 주식 대신 매입

Asia

Equities

Government

Large Cap

Regulations

Broad U.S. Equity ETFs

Econ #s

ETFs

MAGS

NFLX

ORCL

SCHW

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

S&amp;P 500이 수요일에 6,100포인트를 잠시 넘기며 새로운 사상 최고치를 기록했다. 이는 강력한 기업 실적과 도널드 트럼프 대통령의 5,000억 달러 규모의 인공지능(AI) 투자 계획인 &#34;AI 스타게이트&#34;의 발표로 월가가 긍정적으로 반응한 결과이다.

S&amp;P 500가 6,100의 최고가를 경신: 강력한 기업 실적, 트럼프의 AI 베팅이 상승을 격려

<a href="https://www.dailymail.co.uk/galleries/article-14422269/New-coronavirus-pandemic-potential-discovered-China.html">https://www.dailymail.co.uk/galleries/article-14422269/New-coronavirus-pandemic-potential-discovered-China.html</a>
&nbsp;

Biotech

Macro Economic Events

Global

Economics

General

BNTX

MRNA

NVAX

'New Coronavirus With Pandemic Potential Discovered In China' - DailyMail

The only SC induction data for an IL-23 inhibitor show statistically significant and clinically meaningful improvements across clinical and endoscopic measures versus placebo, consistent with IV induction.
 &nbsp;

Johnson & Johnson To Present Data From Phase 3 ASTRO Study Of TREMFYA SC Induction Therapy At ECCO; Says Study Achieved Primary And All Secondary Endpoints At Week 12 In Ulcerative Colitis Patients

NVIDIA&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)&nbsp;has&nbsp;introduced Evo 2, an advanced artificial intelligence (AI) system aimed at transforming the field of biological research.
What Happened: Nvidia announced on Wednesday, that Evo 2, its new AI model, is set to fast-track advancements in genetics and medicine by rapidly analyzing and generating genetic code from a wide range of organisms. According to Nvidia, this project &#8216;provides insights into DNA, RNA and proteins across diverse species.&#8217; The system is being recognized as the most comprehensive AI system to date for biological research.
This project has been undertaken on the NVIDIA DGX Cloud platform in association with Stanford University and Arc Institute, a nonprofit&nbsp;research center,&nbsp;with an outlay of $650 million.
Evo 2 is designed to significantly speed up research processes that traditionally require extensive manual data analysis. The system has been trained on nearly 9 trillion nucleotides&nbsp;or genetic data points from more than 128,000 diverse organisms, including bacteria, plants, and humans.
In early trials, Evo 2 accurately detected 90% of potentially harmful mutations in BRCA1, a gene associated with breast cancer. The model was built using 2,000 Nvidia H100 processors on Amazon&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) cloud infrastructure, Amazon Web Services. 
According to Nvidia, Evo 2 could also help in&nbsp;healthcare and drug discovery through gene variant analysis. Additionally, its&nbsp;insights into plant biology could empower scientists to design varieties of climate-resistant crops and address global food shortages.
SEE ALSO: <a href="https://www.benzinga.com/markets/equities/25/02/43811296/walmart-set-for-record-sales-amid-tariff-concerns-one-of-the-better-positioned-retailers-to-mitigate-or-manage-through-tariffs-says-analyst">Walmart Set For Record Sales Amid Tariff Concerns: &#8216;One Of The Better-Positioned Retailers To Mitigate Or Manage Through Tariffs&#8217;, Says Analyst</a>
Why It Matters: The release of EVO 2 reinforces Nvidia&#8217;s AI goals in exploring healthcare and biomedical fields as a means to diversify its revenue verticals. 
In March, the company revealed partnerships with Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) to utilize generative AI in surgery and with GE Healthcare, an arm of the General Electric Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) to enhance medical imaging. In the past, the chipmaker also launched nearly&nbsp;two dozen AI-powered tools focussed on healthcare besides investing $50 million in 2023 into a biotech firm, Recursion, for AI-powered drug discovery. 
Meanwhile, top Wedbush analyst Dan Ives predicted that <a href="https://www.benzinga.com/25/02/43837526/top-analyst-predicts-apple-will-hit-4-trillion-first-followed-by-nvidia-says-ai-demand-is-exploding-despite-tariffs-and-deepseek-fears-the-bears-cant-see-ai-in-the-spreadsheets">NVIDIA would follow</a> Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) in reaching a $4 trillion market cap, despite concerns over tariffs and rising competition from China&#8217;s DeepSeek. The analyst remained bullish on AI stocks, emphasizing the inability of &#8220;bears&#8221; to see the potential of AI in the spreadsheets. The launch of Evo 2 underscores this potential and NVIDIA&#8217;s leading role in the AI revolution.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/25/02/43829643/stroke-device-maker-penumbra-stock-surges-on-earnings-beat-upbeat-2025-outlook-analysts-boost-price-forecasts">Stroke Device Maker Penumbra Stock Surges On Earnings Beat, Analysts Boost Price Forecasts After Upbeat 2025 Outlook</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

NVIDIA's New AI System Aims To Transform Genetic Research With Unmatched Speed And Precision

Investors are scrambling to assess the potential fallout of yet <a href="https://www.benzinga.com/topic/tariffs">another tectonic trade decision</a>. 
What Happened: President Donald Trump plans to impose a 25% levy on <a href="https://www.benzinga.com/25/02/43805852/trump-shakes-global-trade-with-25-auto-chip-and-pharma-tariffs-announcement-asian-stocks-pare-their-five-day-rally">auto, semiconductor, and pharmaceutical imports</a>,
This move could have far-reaching consequences for <a href="https://www.benzinga.com/etfs">ETFs with heavy exposure to these sectors</a>, particularly those tracking automakers, chipmakers, and biotech firms.
Trump's protectionist stance triggered an immediate market response across the global markets. Asian stocks retreated after a five-day rally, with the MSCI Asia Pacific Index slipping, particularly affecting Japanese automakers like Toyota Motor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>).
Also Read: <a href="https://www.benzinga.com/news/global/25/02/43795579/warren-buffett-unfazed-by-trumps-tariff-threats-oracle-of-omaha-bets-on-mexico-beer">Warren Buffett Unfazed By Trump&#8217;s Tariff Threats: Oracle Of Omaha Bets On Mexico, Beer</a>
Automakers: The U.S. imported around 8 million passenger cars and light trucks last year, comprising 50% of total vehicle sales, according to a report by Wall Street Journal. A 25% tariff would increase vehicle prices, impact supply chains, and hurt companies dependent on overseas manufacturing. 
Here are a few ETFs likely to take a hit:
<ul>
<li>Global X Autonomous &amp; Electric Vehicles ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIV#NASDAQ">DRIV</a>): Fairly exposed to Toyota, Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), and Ford (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), this fund could face turbulence as trade tensions mount.</li>
</ul>
<ul>
<li>First Trust NASDAQ Global Auto Index Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARZ#NASDAQ">CARZ</a>): Tracks major global automakers, including BMW, Honda, and General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>), which rely on imported parts. The ETF also has significant exposure to Toyota and Tesla and allocates 46% of its assets to overseas stocks. That places it in a precarious position amid escalating tariff situations.</li>
</ul>
Chips: Trump also declared that sectoral tariffs on semiconductors would start at "25% or higher", escalating further over time. This comes as the U.S. considers a 100% tariff on Taiwanese semiconductors, an industry heavily reliant on TSMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>).
<ul>
<li>iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) – With Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), and Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) among its top holdings, this fund is exposed to volatility stemming from supply chain disruptions.</li>
</ul>
<ul>
<li>VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>) – Heavily weighted towards TSMC, Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), and Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>), making it vulnerable to any tariff escalation.</li>
</ul>
Pharma: The pharmaceutical sector is also caught in the crosshairs, with Trump hinting at escalating tariffs beyond 25% over the year. This could upend drug pricing, R&amp;D costs, and supply chain dynamics for major biopharma companies.
<ul>
<li>iShares U.S. Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>): Tracks major drugmakers like Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Merck (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), all of which could see higher costs.</li>
</ul>
<ul>
<li>SPDR S&amp;P Biotech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XBI#NYSE">XBI</a>): While biotech firms often have global R&amp;D operations, increased tariffs could disrupt access to imported drug components.</li>
</ul>
Why It Matters: Trump has long voiced concerns over U.S. automotive exports being treated unfairly abroad. In his first term, he threatened a similar 25% car tariff but ultimately backed down.
For ETF investors, volatility is back on the table. Those holding funds exposed to autos, chips, and pharmaceuticals must brace for a bumpy ride. While Trump believes the move will bring manufacturing back home, the short-term pain could be severe.
The Wall Street Journal reported that U.S. companies may receive a phase-in period, with tariffs increasing over the course of the year.
What's Next: Markets will be watching closely as April 2 (when auto tariffs are expected to kick in) approaches. Any delays or modifications to the tariff plan could shift investor sentiment. 
For now, ETF traders should keep an eye on sectoral rotation, hedge exposure where necessary, and prepare for the potential impact of another round of trade wars.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/02/43794873/vanguard-overtakes-state-street-as-top-etf-provider-3-funds-in-focus">Vanguard Overtakes State Street As Top ETF Provider: 3 Funds In Focus</a></li>
</ul>
Photo: Shutterstock

AVGO

CARZ

DRIV

iShares Dow Jones US Pharmaceuticals Index Fund

INTC

QCOM

Trade War Redux: These ETFs Due For Bumpy Ride Thanks To Trump Tariffs On Auto, Pharma, Chip Imports

RBC Capital analyst Shagun Singh reiterates Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Outperform and maintains $181 price target.

Price Target

Reiteration

Analyst Ratings

RBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $181 Price Target

On Tuesday, Axsome Therapeutics Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>)&nbsp;reported fourth-quarter 2024 revenues of $118.77 million, up from $71.53 million a year ago, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $117.64 million.</a>
Auvelity (oral antidepressant) net product sales for the quarter were $92.6 million, up 89% year over year. Approximately 158,000 prescriptions were written for Auvelity in the fourth quarter of 2024, representing an increase of 87% and 10% compared to the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43776882/axsome-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-busin" rel="noreferrer noopener">third quarter of 2024</a>.
Sunosi (sleep disorder) net product revenues were $26.2 million, up 16%. Approximately 49,000 prescriptions were written for Sunosi, representing an increase of 16% year-over-year and 4% sequentially.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43601535/axsome-therapeutics-resolves-generic-patent-litigation-with-teva-over-depression-drug-analyst-maintains-axsome-as-top-pick-for-2025" rel="noreferrer noopener">Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As &#8216;Top Pick For 2025&#8217;</a>
The company reported a net loss of $1.54 per share compared to $2.08 per share a year ago, missing the consensus of $(1.03).
Anticipated Milestones
<ul>
<li>The company expects to submit a new drug application for AXS-14 for fibromyalgia in the first half of 2025, a delay <a href="https://www.benzinga.com/pressreleases/24/11/g41896353/axsome-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-update" target="_blank" rel="noreferrer noopener">from November 2024</a>.</li>
<li>Axsome anticipates new drug application submission for AXS-05 for Alzheimer&#8217;s disease agitation and AXS-12 for narcolepsy in the second half of 2025.</li>
<li>The company expects clinical data from a Phase 3 EMERGE trial of AXS-07 in migraine in 1Q 2025.</li>
<li>Data from Phase 3 FOCUS trial of solriamfetol in ADHD in adults and Phase 3 PARADIGM trial in major depressive disorder in Q1 2025.</li>
<li>The company anticipates data from the Phase 3 ENGAGE trial of solriamfetol in binge eating disorder and the Phase 3 SUSTAIN trial in shift work disorder in 2026.</li>
<li>A pivotal Phase 2/3 trial of AXS-05 in smoking cessation is expected to be initiated in 2025.</li>
</ul>
In January, the FDA approved Axsome Therapeutics&#8217; Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43351848/axsome-therapeutics-announces-fda-approval-of-symbravo-meloxicam-and-rizatriptan-for-the-acute-tre" rel="noreferrer noopener">without aura in adults</a>.
The company expects SYMBRAVO to be commercially available in the U.S. in approximately four months.
William Blair sees Axsome&#8217;s AXS-05 as a unique drug with strong safety advantages. Analyst Myles Minter is optimistic about its approval chances, citing positive results from the ADVANCE-1, ACCORD-1, and ACCORD-2 trials and its breakthrough therapy designation.
With peak sales expected to surpass $1 billion for Alzheimer &#8216;s-related agitation, William Blair considers this expansion a major growth driver for Axsome. The firm also notes potential M&amp;A interest, especially given Johnson &amp; Johnson&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42948170/like-bristol-myers-squibb-and-abbvie-johnson-johnson-seeks-to-bolster-neuropsychiatric-portfolio-with-15-billion-deal" rel="noreferrer noopener">pending $14.6 billion</a> acquisition of Intra-Cellular Therapies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>).
Price Action:&nbsp;AXSM shares are down 3% at $127.22&nbsp;on the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43776626/totalenergies-powers-up-with-air-liquide-in-a-628-million-hydrogen-breakthrough" target="_blank" rel="noreferrer noopener">TotalEnergies Powers Up With Air Liquide For Hydrogen Breakthrough</a></li>
</ul>

Movers

AXSM

ITCI

Axsome's AXS-05 In Alzheimer's Agitation Could Be Billion Dollar Opportunity, Says Analyst

Former U.S. Secretary of Labor Robert Reich has called out the tax reduction plans of the Donald Trump-led administration in an X post, terming them as an &#8220;absolutely shameless giveaway,&#8221; that could shoot up the deficit by $4.6 trillion.
What Happened: The possible tax cuts for rich individuals and lower corporate tax rates are likely to widen the U.S. trade deficit, which the Trump 2.0 administration would most likely fund from the tariffs imposed on its trading partners.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Trump wants to extend his tax cuts for rich individuals, which would add $4.6T to the deficit. But he wants to go even further, cutting the corporate tax rate to 15%. It&#39;s yet another absolutely shameless giveaway. <a href="https://t.co/mkAWOFkkUd">pic.twitter.com/mkAWOFkkUd</a>
&mdash; Robert Reich (@RBReich) <a href="https://twitter.com/RBReich/status/1891623719304339516?ref_src=twsrc%5Etfw">February 17, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The data from the Center For American Progress Action Fund or CAPAF shows that cutting the corporate tax rate down to 15% would save all sectors and companies billions of dollars in tax.
<ul>
<li>Top 100 U.S. Companies: Can expect a total annual tax cut of $48 billion despite reporting $1.1 trillion in profits in their 2023 annual report.</li>
</ul>
<ul>
<li>Top 10 U.S. Companies: Reported more than $520 billion in profits according to their 2023 annual report can expect an annual tax cut of $23 billion. These include firms like Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Comcast Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>), and JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>).</li>
</ul>
<ul>
<li>Oil: The five largest U.S. oil companies, including Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>), Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>), Marathon Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>), Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>), and Valero Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>) will receive an estimated $2.2 billion annual tax cut, despite over $80 billion in profits.</li>
</ul>
<ul>
<li>Pharma: The five largest U.S. drug makers, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Merck &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) and Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) will receive an estimated $3.1 billion annual tax cut, despite over $50 billion in profits.</li>
</ul>
<ul>
<li>Banking: The five largest Wall Street banks, JPMorgan Chase, Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>), Wells Fargo &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) and Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) will receive an estimated $4.1 billion annual tax cut, despite nearly $113 billion in profits.</li>
</ul>
<ul>
<li>Grocery: The five largest grocery companies, Kroger Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>), Costco Wholesale Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>), Albertsons Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>), Target Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) and Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) will receive an estimated $1.7 billion annual tax cut, despite over $29 billion in profits.</li>
</ul>
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43763438/trump-acting-like-a-mafia-don-says-this-economist-as-uncertainty-mounts-businesses-hold-back-in-fear-of-unforeseen-economic-shifts">Trump &#8216;Acting Like A Mafia Don,&#8217; Says This Economist As Uncertainty Mounts, Businesses Hold Back In Fear Of Unforeseen Economic Shifts</a>
Why It Matters: Trump has threatened all its trading partners with &#8220;reciprocal tariffs,&#8221; while already having implemented 25% on steel and aluminum imports.
According to economists like Craig Shapiro, who is a macro strategist at the Bear Traps Report, tariffs are the "<a href="https://www.benzinga.com/25/02/43587245/tariffs-are-the-only-way-to-fund-tax-cuts-without-deficit-expansion-argues-expert-as-it-takes-center-stage-in-donald-trumps-economic-plan">only way</a>" to fund tax cuts without expanding the federal deficit. 
Shapiro likened Trump&#8217;s governance to that of a &#8220;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43763438/trump-acting-like-a-mafia-don-says-this-economist-as-uncertainty-mounts-businesses-hold-back-in-fear-of-unforeseen-economic-shifts">Mafia Don</a>,&#8221; saying businesses are now uncertain about the economy&#8217;s direction. He noted fading &#8220;initial euphoria&#8221; and a &#8220;wait-and-see&#8221; approach from business leaders due to unclear policies, tariffs, trade agreement uncertainty, and fluctuating government spending. &#8211;
Price Action: On Friday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) which track the S&amp;P 500 and Nasdaq 100 indices, closed mixed. SPY fell 0.0049% to a value of $609.7, and QQQ was up by 0.42% to end at a value of $538.15, according to Benzinga Pro data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/02/43773441/ahead-of-gamestops-bitcoin-purchase-plans-blackrock-morgan-stanley-goldman-sachs-and-other-billion-dollar-funds-load-up-on-gme-stock-in-q4">Ahead Of GameStop&#8217;s Bitcoin Purchase Plans, BlackRock, Morgan Stanley, Goldman Sachs, And Other Billion Dollar Funds Load Up On GME Stock In Q4</a></li>
</ul>
Photo courtesy: Shutterstock

Macro Notification

ABBV

CMCSA

COST

Trump's Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich

<a href="https://www.fda.gov/medical-devices/medical-device-recalls/heart-pump-recall-abiomed-inc-updates-use-instructions-impella-rp-smartassist-and-impella-rp-flex" title="https://www.fda.gov/medical-devices/medical-device-recalls/heart-pump-recall-abiomed-inc-updates-use-instructions-impella-rp-smartassist-and-impella-rp-flex">https://www.fda.gov/medical-devices/medical-device-recalls/heart-pump-recall-abiomed-inc-updates-use-instructions-impella-rp-smartassist-and-impella-rp-flex</a>

Reported Feb. 13, 2025: FDA Announces "Heart Pump Recall: Abiomed, Inc. Updates Use Instructions for Impella RP with SmartAssist and Impella RP Flex with SmartAssist Due to A Risk That the Tip of Guidewires or Other Medical Devices May Come into Contact with The Impella Pump During Insertion, Adjustment, Or Removal"

Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) have discontinued the E.mbrace phase 3 study evaluating a vaccine candidate for extraintestinal pathogenic&nbsp;E. coli.
The E.mbrace <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-02-13-06-00-00-3025576" rel="noreferrer noopener">study</a> is a randomized, double-blind, placebo-controlled, multicenter, interventional phase 3 study evaluating the efficacy, safety, and immunogenicity of a single dose of the vaccine candidate compared to a placebo in the prevention of IED, which includes sepsis and bacteremia (blood infections).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43142442/sanofi-genzyme-facility-fda-quality-lapses" rel="noreferrer noopener">Sanofi Genzyme Facility Draws FDA Criticism Over Alleged Quality Lapses</a>
An independent data monitoring committee (IDMC) conducted a scheduled review of the E.mbrace phase 3 study.
The companies determined that the vaccine candidate was not sufficiently effective at preventing invasive&nbsp;E. coli disease (IED) compared to placebo.
No safety signals related to the vaccine candidate were identified, and throughout the study, investigators ensured that participants who developed IED received prompt treatment and care.
In October 2023, Sanofi entered into an agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson &amp; Johnson company, to develop and commercialize the vaccine candidate.
Under the terms of the agreement, both parties agreed to co-fund current and future research and development costs. Sanofi paid $250 million in upfront and development milestones to be followed by commercial milestones.
The study was initiated in June 2021 enrolling adults aged 60 years or older in stable health with a history of urinary tract infection in the past two years.
As a result of the discontinuation, Sanofi has recorded an impairment charge before tax of $250 million in the Q4 2024 IFRS results. This adjustment negatively impacts the full-year IFRS EPS reported in the Q4 2024 results press release on January 30, 2025, by 15 cents, from 4.59 euros previously to 4.44 euros now.
However, there is no impact on the business net income/EPS, which remain unchanged, respectively, at 8.91 billion euros/ 7.12 euros (non-IFRS).
Price Action: As of Thursday, SNY stock was up 0.18% at $54.66 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43676723/third-harmonic-bio-initiates-strategic-review-lays-off-50-staff-citing-competitive-landscape" target="_blank" rel="noreferrer noopener">Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape</a></li>
</ul>
Image by HJBC via Shutterstock

Health Care

Contracts

Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study

Published results reinforce the high-affinity binding and immunoselective properties of nipocalimab, which has been shown to reduce IgG levels by &gt;75%, including autoantibodies, potentially without affecting other immune functions
SPRING HOUSE, Pa., Feb. 13, 2025 /PRNewswire/ --&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced the publication of data detailing the differentiated molecular properties of nipocalimab, an investigational neonatal Fc receptor (FcRn) blocker, <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4358266-1&amp;h=2875384473&amp;u=https%3A%2F%2Fdoi.org%2F10.1080%2F19420862.2025.2461191&amp;a=in+mAbs">in mAbs</a>.a This publication highlights the selective, targeted and high-affinity binding properties of nipocalimab which support its differentiated potential as a treatment option for immunoglobulin G (IgG)-driven alloantibody and autoantibody diseases.1
Nipocalimab is a fully human IgG-1 monoclonal antibody that binds to FcRn, resulting in the reduction of circulating IgG levels including pathogenic IgG autoantibodies.1 The studies established that nipocalimab binds both specifically and with high, pH-independent affinity to FcRn.1 These preclinical studies also established the relationship between FcRn binding and the inhibition of IgG recycling, revealing that nipocalimab achieves time and dose-dependent IgG reductions of greater than 75% without affecting IgG production and without detectable effects on other adaptive and innate immune functions.1 The pH-independent nature of the binding, also noted in this publication, is one factor contributing to the ability to investigate nipocalimab in alloimmune diseases of pregnancy.1 The mechanism of action of nipocalimab was assessed through in vitro and in vivo studies, and attributes noted in the publication are consistent with clinical Phase 1, 2 and 3 studies of nipocalimab.1 The clinical significance is not yet known.&nbsp;

Johnson & Johnson Announces New Nipocalimab Data Published In Mabs Journal Details Differentiated Molecular Design, Clinical Profile And Potential Of Nipocalimab To Treat IgG-Driven Alloantibody And Autoantibody Diseases

Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
<ul>
<li>Independent interim analysis of the E.mbrace phase 3 study finds that the vaccine candidate didn't demonstrate sufficient efficacy in preventing invasive E. coli disease</li>
<li>No safety signals related to the vaccine candidate were identified</li>
</ul>
Financial considerations As a result of the discontinuation, Sanofi has recorded an impairment charge before tax of $250 million in the Q4 2024 IFRS results. This adjustment impacts negatively the full-year IFRS EPS reported in the Q4 2024 results press release on January 30, 2025, by €0.15 from €4.59 previously to €4.44 now. This adjustment&nbsp;will be included&nbsp;in Sanofi's Form 20-F for 2024 to be filed with the US Securities and Exchange Commission. However, there is no impact to the business net income / business EPS remaining unchanged respectively at €8,912 million / €7.12 (non-IFRS). There is no change to the financial guidance for 2025

Sanofi And Janssen Halt Phase 3 E. coli Vaccine Trial Following Interim Analysis Showing Insufficient Efficacy; Sanofi Records €250M Impairment Charge

One of the most active members of buying and selling stocks in recent years has been U.S. Rep. Josh Gottheimer (D-N.J.), who recently disclosed dozens of new transactions as reported by <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent021225">Benzinga's Government Trades page.</a>
What Happened: The<a href="https://www.benzinga.com/topic/congress-trading"> trading activity of members </a>of Congress has come under pressure in recent years with retail investors and politicians actively monitoring the activity to see if there are conflicts of interest.
Gottheimer recently disclosed a long list of purchases and sales of stocks, all with a $1,000 to $15,000 value. View the full list of trades at<a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent021225"> Benzinga's Government Trades page.</a>
Here are some of the trades that stand out in the list of transactions, with the stock purchases and buys all made from Jan. 8 through Jan. 31.
<ul>
<li>Sold NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>): The transaction log shows four separate sales of Nvidia stock meaning a total of $3,000 to $45,000 in NVDA shares sold. The move comes with Nvidia stock one of the top performers of the last year.</li>
<li>Bought Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>): Gottheimer bought Tesla stock in three separate transactions, totaling a range of $3,000 to $45,000.</li>
<li>Bought Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>): Bought Visa stock five transactions, meaning a total of $5,000 to $75,000 in stock.</li>
<li>Bought and Sold Mastercard Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>): In the transaction report, Gottheimer disclosed two purchases of Mastercard and one sale.</li>
<li>Sold Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>): Gottheimer also sold Microsoft stock in the reporting period with three separate transactions.</li>
<li>Bought Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>): The Congressman bought Johnson &amp; Johnson shares with three transactions totaling $3,000 to $45,000</li>
</ul>
Many of the buys and sells cover the technology sector with some buying of blue-chip names like Johnson &amp; Johnson, Coca-Cola and Berkshire Hathaway.
Read Also: <a href="https://www.benzinga.com/politics/25/02/43663526/elon-musk-questions-congress-members-wealth-where-did-they-get-all-the-money">Elon Musk Questions Congress Members&#8217; Wealth: &#8216;Where Did They Get All The Money?&#8217;</a>
Why It's Important: Gottheimer has made thousands of stock buys and sells in recent years and is one of the most active members of Congress when it comes to his trading activity.
While recent sells could be profit taking or for tax purposes, the timing of selling semiconductor stocks like Nvidia, Taiwan Semiconductor and Broadcom could be questionable given the potential battle with China on export restrictions and new tariffs.
Gottheimer ditched Nvidia and Microsoft stock and chose a different Magnificent 7 stock instead in Tesla. The move will likely be closely followed given Tesla CEO Elon Musk's close working relationship with President Donald Trump, which could lead to favorable contracts and regulation for Tesla.
Gottheimer serves on the Committee on Financial Services, which could make the timing of the purchases of Visa and Mastercard stock questionable also.
In 2023, Gottheimer had the <a href="https://www.benzinga.com/general/politics/24/01/36459015/10-best-stock-traders-in-congress-in-2023-spoiler-nancy-pelosi-is-back-on-the-list">three best trades </a>as tracked by Unusual Whales with two sales of Meta Platforms profiting over 100% each and a third trade of Monster Beverage also profiting over 100%. Gottheimer also had the best tracked <a href="https://www.benzinga.com/government/23/01/30260466/10-best-stock-traders-in-congress-in-2022-spoiler-nancy-pelosi-isnt-no-1">trade in 2022</a>, with Amgen acquiring ChemoCentryx making a 140% return for the Congressman.
Check This Out:
<ul>
<li><a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent021225">Lawmakers Are Making Huge Investments In 2025. See What They&#8217;re Buying And Selling With Our Easy-to-Use Tool</a></li>
</ul>
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent021225"><img loading="lazy" decoding="async" width="1024" height="330" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12171436/Picture1-3-1024x330.png" alt="" class="wp-image-779783" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12171436/Picture1-3-1024x330.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12171436/Picture1-3-300x97.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12171436/Picture1-3-768x248.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12171436/Picture1-3.png 1430w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Photo courtesy of Josh Gottheimer&#8217;s official webpage

Congress Member Josh Gottheimer Dumps Nvidia, Microsoft, Loads Up On Tesla Stocks Instead

STLA

House Speaker Johnson Says He Believes The White House Is Considering Exemptions To Reciprocal Tariffs Including Autos And Pharmaceuticals

In the current market session, Johnson &amp; Johnson Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) share price is at $155.27, after a 0.55% decrease. Over the past month, the stock increased by 7.24%, but over the past year, it actually fell by 0.81%. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

<img src="https://www.benzinga.com/files/images/story/2025/1739371513_0.png" alt="Past Year Chart" />

<h3>Comparing Johnson &amp; Johnson P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 27.1 in the Pharmaceuticals industry, Johnson &amp; Johnson Inc. has a lower P/E ratio of 26.97. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1739371513_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

P/E Ratio Insights for Johnson & Johnson

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) is reportedly considering selling its stroke care unit, Cerenovus, in a deal that could value the business at more than $1 billion.
The move aligns with the company&#8217;s ongoing efforts to streamline its medical technology division following a series of acquisitions.
The healthcare giant has engaged advisers to gauge interest from private equity firms and strategic buyers.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43174150/johnson-johnsons-medtech-momentum-expected-to-rebound-in-2025-despite-current-hurdles-analyst" rel="noreferrer noopener">Johnson &amp; Johnson&#8217;s MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst</a>
Monday&#8217;s Financial Times <a target="_blank" href="https://www.ft.com/content/b2a52b96-121e-469e-b4a3-5b6c3ab2994b" rel="noreferrer noopener">report</a>, citing sources, indicates that Cerenovus, which develops surgical tools for stroke treatment, could fetch between $1 billion and $1.5 billion.
Johnson &amp; Johnson has aggressively expanded its medtech portfolio, spending over $30 billion on acquisitions in the past three years.
In 2022, Johnson &amp; Johnson acquired Abiomed for an upfront payment of $380.00 per share, corresponding to an enterprise value of <a target="_blank" href="https://www.benzinga.com/news/earnings/22/11/29499801/johnson-johnson-expands-cardiovascular-portfolio-bets-16b-in-abiomeds-heart-failure-devices" rel="noreferrer noopener">approximately $16.6 billion</a>.&nbsp;
In 2024, Johnson &amp; Johnson&nbsp;acquired&nbsp;Shockwave Medical for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion,&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38147469/johnson-johnsons-13b-shockwave-medical-deal-accelerates-medtech-strategy-analyst-sa" rel="noreferrer noopener">including cash acquired</a>.&nbsp;
In August, Johnson &amp; Johnson made a tuck-in deal to acquire V-Wave for an upfront payment of $600 million, with the potential for additional regulatory and commercial milestone payments up to&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40464864/johnson-johnson-strikes-1-7b-deal-to-acquire-heart-tech-innovator-v-wave" rel="noreferrer noopener">approximately $1.1 billion</a>. V-Wave is a privately held medical device company focused on developing heart failure and cardiovascular disease treatment options.
In 2024, the company&#8217;s MedTech unit generated sales of $31.8 billion, up 4.8% or 6.2% operationally, with Shockwave and Abiomed as part of the <a target="_blank" href="https://www.benzinga.com/25/01/43125966/johnson-johnson-reports-q4-earnings-above-wall-street-estimates-driven-by-strong-cancer-drugs-revenue" rel="noreferrer noopener">primary operational drivers</a>.
Citing Jefferies Analysts, the Financial Times report adds that Johnson &amp; Johnson has one of the strongest cash and debt capacities for future deals.
Price Action: JNJ stock is down 0.49% at $155.36 during the premarket session on last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43637871/alibaba-clouds-growth-accelerates-with-ai-analyst-weighs-deepseeks-rising-competition" target="_blank" rel="noreferrer noopener">Alibaba Cloud&#8217;s Growth Accelerates With AI, Analyst Weighs DeepSeek&#8217;s Rising Competition</a></li>
</ul>
Photo by Tada Images via Shutterstock

Eurozone

Rumors

Johnson & Johnson Explores Sale of Stroke Device Maker Cerenovus As MedTech Overhaul Accelerates

<a href="https://www.ft.com/content/b2a52b96-121e-469e-b4a3-5b6c3ab2994b" title="https://www.ft.com/content/b2a52b96-121e-469e-b4a3-5b6c3ab2994b">https://www.ft.com/content/b2a52b96-121e-469e-b4a3-5b6c3ab2994b</a>

'Johnson & Johnson Puts Stroke Care Business Up For Sale' - Finacial Times

Warren Buffett's granddaughter Nicole Buffett says she was cut off financially and emotionally after speaking publicly about wealth inequality. Nicole, who was legally adopted by <a href="https://www.benzinga.com/personal-finance/24/10/41198368/warren-buffetts-son-who-famously-cashed-in-his-90-000-inheritance-at-19-spends-millions-in-buffe">Buffett's son Peter</a>, described how her relationship with her grandfather soured after she appeared in "The One Percent," a 2006 documentary by Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) heir Jamie Johnson.
"My grandfather is a very private man, and I decided to share what it's like to be his granddaughter, and it created a huge estrangement from him to the extent that he disowned my twin sister and myself," she told <a href="https://www.reuters.com/article/lifestyle/documentary-on-wealth-gap-divides-buffett-family-idUSN20404370/">Reuters in 2008</a>.
Despite not being biologically related, Nicole spent time with Warren growing up. She recalled receiving a $100 bill from him for Christmas when she was 5 and being given a private tour of the See's Candies factory. The family also vacationed at Warren's Laguna Beach home twice a year.&nbsp;
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
</ul>
But while she experienced glimpses of the Buffett lifestyle, she was also expected to be financially independent. Warren covered her six-figure college tuition but maintained a strict policy of funding only education-related expenses. When she once asked for help buying a futon, his secretary reportedly reminded her of the rule.
In a 2008 <a href="https://www.marieclaire.com/culture/news/a2342/warren-buffett-granddaughter-nicole-buffett/">Marie Claire article</a>, Nicole described how being cut off left a permanent divide. "For him to discard me like that was devastating. It permanently divided our family," she said. She also explained that she was unaware of the full scope of Warren's wealth until she was 17 when he appeared on the cover of Forbes as America's richest man.
Trending: Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.
Her decision to participate in "The One Percent" was a breaking point. Nicole spoke about wealth inequality and <a href="https://www.benzinga.com/personal-finance/25/02/43496879/elon-musk-said-warren-buffett-managed-to-create-a-great-image-as-a-kindly-grandfather-but-thinks-thats-maybe-overstating-the-case">her grandfather's philosophy</a> on money, saying in the documentary, "Money is the spoke in my grandfather's wheel of life." Soon after, she received a letter from Warren stating: "I have not emotionally or legally adopted you as a grandchild, nor have the rest of my family adopted you as a niece or a cousin." To make it even clearer, he signed the letter "Warren" instead of "Grandpa."
Nicole later appeared on "Oprah," further discussing the family's financial views. Warren, who has publicly committed to donating the majority of his fortune to charity rather than passing it down to his children and grandchildren, was reportedly unhappy with the attention.
See Also: The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?
In the Marie Claire interview, Nicole revealed was living on $40,000 a year without cable TV or health insurance, far from what most people imagine when they hear the Buffett name. "The first thing most people think of when they hear my last name is money," she said.
Despite being cut off, she has since found success in the NFT art world, creating a series called Spirit Coins, which combines her traditional art background with digital technology. While her <a href="https://www.benzinga.com/personal-finance/25/01/43166526/billionaire-warren-buffetts-first-wife-said-he-cared-about-the-win-not-the-money-its-all-mental-with-him-and-money-is-his-scorecard">financial ties to the Buffett </a>empire have been severed, Nicole has carved out her own path, even if it looks nothing like the life she once knew.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
</ul>

Personal Finance

Warren Buffett's Granddaughter Claimed He Cut Her Off And She Couldn't Afford Health Insurance: 'He Disowned My Twin Sister And Myself'

On Friday, Eli Lilly And Cao (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) announced the results from the VIVID-2 open-label extension study of Omvoh&nbsp;(mirikizumab-mrkz).
In January, the FDA approved&nbsp;Omvoh for moderately to severely active Crohn's&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43053632/fda-approves-expanded-use-of-eli-lillys-ulcerative-colitis-drug-for-crohns-disease" rel="noreferrer noopener">disease in adults</a>.
Omvoh is now approved in the U.S. for two types of inflammatory bowel disease (IBD), following its&nbsp;October 2023&nbsp;approval as a first-in-class treatment for moderately to severely active ulcerative colitis (UC) in adults.
The trial showed that most patients with moderately to severely active Crohn's disease received two years of continuous treatment with Omvoh and achieved long-term clinical and endoscopic outcomes, including those (43.8%) with previous biologic failure.
<ul>
<li>Among patients in clinical remission at one year in VIVID-1, 92.9% maintained clinical remission at two years.</li>
<li>Among patients treated in VIVID-2, 87.6% maintained endoscopic response, defined by visible healing of the intestinal lining.</li>
<li>Among patients in endoscopic remission at one year of treatment in VIVID-1, 78.6% maintained endoscopic remission at two years.</li>
</ul>
Additionally:
<ul>
<li>Among patients not in clinical remission at one year, 60.8% gained clinical remission during the second year of treatment.</li>
<li>Among patients not in endoscopic remission at one year, 35.4% gained endoscopic remission during the second year of treatment.</li>
</ul>
In VIVID-2, Omvoh's long-term safety profile in patients with moderately to severely active Crohn's disease was generally consistent with its known safety profile.
In October, Eli Lilly announced data from a VIVID-1 Phase 3 study that evaluated the safety and efficacy of mirikizumab compared with a placebo and active control (Johnson &amp; Johnson's&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jnj#NYSE">JNJ</a>) Stelara (ustekinumab)) in adults with moderately to severely&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41314649/more-patients-on-eli-lillys-mirikizumab-achieved-histologic-response-at-one-year-compared-to-john" rel="noreferrer noopener">active Crohn's disease</a>.&nbsp;
The data showed that more patients who achieved&nbsp;histologic response were observed with mirikizumab at Week 52 in the overall population (58.2% versus 48.8%; p=0.0075).
Data from two Phase 3 studies of mirikizumab across two types of&nbsp;inflammatory bowel diseases showed patients treated with mirikizumab sustained stable, long-term remission in ulcerative colitis <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41580394/eli-lillys-mirikizumab-shows-long-term-sustained-efficacy-safety-for-ulcerative-colitis-and-crohn" rel="noreferrer noopener">and Crohn's disease</a>.
Price Action: LLY stock is up 0.20% at $872.14 during the premarket session on last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/02/43555852/jeep-maker-stellantis-expands-ai-push-with-mistral-ai-partnership-details" target="_blank" rel="noreferrer noopener">Jeep Maker Stellantis Expands AI Push With Mistral AI Partnership: Details</a></li>
</ul>
Photo by Jonathan Weiss via Shutterstock

Eli Lilly's Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years

Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) short percent of float has risen 4.41% since its last report. The company recently reported that it has 17.20 million shares sold short, which is 0.71% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.07 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Johnson &amp; Johnson Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738865712_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Johnson &amp; Johnson has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Johnson &amp; Johnson's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Johnson &amp; Johnson's peer group average for short interest as a percentage of float is 4.13%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(JNJ) - Analyzing Johnson & Johnson's Short Interest

Guggenheim analyst Vamil Divan maintains Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Neutral and raises the price target from $162 to $166.

Guggenheim Maintains Neutral on Johnson & Johnson, Raises Price Target to $166

Press Releases

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet Neurology

Johnson & Johnson champions first-ever Canadian consensus paper identifying critical gaps in psoriasis care for patients with skin of colour

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ

Johnson & Johnson to Participate in the 45th Annual TD Cowen Healthcare Conference

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ

New nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody diseases

GeminiBio Appoints Mike Stella to Board

TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis

AMGN

BDRX

SWKH

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

RBC Capital

Guggenheim

Barclays

Morgan Stanley

Stifel

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

Comments

Johnson & Johnson

Johnson & Johnson (JNJ) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌